Home/Pipeline/Next-Gen α7 NAM Program

Next-Gen α7 NAM Program

CNS Disorders

Discovery/PreclinicalActive

Key Facts

Indication

CNS Disorders

Phase

Discovery/Preclinical

Status

Active

Company

Neuphoria Therapeutics

About Neuphoria Therapeutics

Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.

View full company profile

Therapeutic Areas

Psychiatry Neurology

Other CNS Disorders Drugs

Drug	Company	Phase	Status
NanoBUP™	Nanopharmaceutics	Clinical	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
NP-18-2	Nanopharmaceutics	Clinical	Active
NP-18-3	Nanopharmaceutics	Clinical	Active
LPH-48	Lophora	Pre-clinical	Active
Research Collaboration with OliX Pharmaceuticals	Vect-Horus	Research	Active
ANAVEX®1-41	Anavex Life Sciences	Preclinical	Preclinical
New Discovery Programs	CAMP4 Therapeutics	Discovery	Active discovery